U.S. Banks Stock News

BridgeBio Pharma has announced that long-term efficacy and safety results from the open-label extension of its Phase 3 ATTRibute-CM trial of acoramidis in ATTR-CM, including multiple analyses on survival, disease stabilization, and patient-reported outcomes, were presented at the American College of Cardiology Annual Scientific Sessions in New Orleans on March 28–30, 2026. The new data, alongside real-world survey findings on treatment patterns and preferences in ATTR-CM, offer a deeper view...

If you are wondering whether Global-E Online is starting to look attractive or still carries too much risk, its recent share price moves and current valuation metrics give you plenty to think about. The stock last closed at US$28.93, with returns of a 10.5% decline over 7 days, a 17.6% decline over 30 days, a 23.6% decline year to date and an 18.9% decline over 1 year. These moves may have shifted how the market is pricing its prospects and risks. These moves have come as Global-E Online...

H.B. Fuller (NYSE:FUL) secured key raw materials after more than 40 force majeure notices linked to Middle East related supply disruptions. The company plans a minimum 10% global price increase effective April 1, 2026, to address inflation and raw material cost pressures. Management has paused acquisitions to focus on debt reduction and share buybacks, which signals a shift in capital allocation priorities. For investors watching NYSE:FUL, the share price sits at $59.17, with a 20.0% gain...

In March 2026, Alteogen announced an exclusive license deal giving Biogen rights to develop subcutaneous formulations for two biologic products using ALT-B4 Hybrozyme technology, while new data from Eisai and Biogen showed strong long-term real-world treatment persistence for intravenous lecanemab in Alzheimer’s patients. Together, these developments highlight Biogen’s push to expand patient-friendly biologic delivery and deepen its presence in Alzheimer’s care through therapies patients are...

Revvity (NYSE:RVTY) plans to hold its annual meeting on April 28, 2026. Shareholders will vote on a proposed bylaw change to let holders of 25% of shares call special meetings. Activist-backed proposals seek tighter executive stock retention requirements tied to equity compensation. Revvity, which operates in life sciences and diagnostics, sits in a sector where governance practices are closely watched, partly because R&D cycles and regulatory oversight can shape capital allocation...

If you are wondering whether eToro Group at around US$29.05 is a bargain or a value trap, this breakdown is designed to help you frame that question clearly. The share price closed at US$29.05, with a 1.3% decline over the past week, a 10.5% decline over the past month, and an 18.6% decline year to date, which may signal shifting views on both risk and potential. Recent coverage has focused on eToro Group as a publicly listed trading platform provider that gives investors access to a wide...

If you are wondering whether Cabot's current share price reflects its true worth, this article breaks down the key valuation clues you can use to judge it for yourself. Cabot recently closed at US$74.11, with returns of 9.3% over the past week, a 2.3% decline over the past month, 10.5% year to date and a 7.7% decline over the past year. Taken together, these figures give mixed signals about how the market is currently pricing the stock. Recent coverage around Cabot has focused on its...

Wondering if PTC Therapeutics at around US$66.13 is giving you a fair deal or asking too much for its future potential? This article breaks down what the current price might be implying. The stock has seen a mixed run recently, with a 1.3% gain over the last 7 days, a 2.4% decline over 30 days, a 13.8% decline year to date, a 21.9% return over 1 year, and 36.5% and 34.4% over 3 and 5 years respectively. Recent attention on PTC Therapeutics has centered on how investors are reassessing the...

Wondering if Generac Holdings at around US$194 per share still offers value, or if the easy gains are already behind it? This article focuses squarely on what the current price implies. The stock has had a mixed run, with a 2.5% decline over the last week and a 17.8% decline over the last month, while still sitting on returns of 37.8% year to date and 53.0% over the past year. Recent coverage of Generac has highlighted renewed interest in companies linked to backup power and grid resilience...

For readers wondering whether Brunswick's share price still offers value after a strong run, or if most of the potential upside is already reflected, this article focuses on what the numbers indicate about its valuation. Brunswick closed at US$70.95, with a 0.7% return over the last 7 days, a 12.4% decline over 30 days, a 6.5% decline year to date, and a 36.2% gain over 1 year. Over 3 years and 5 years the returns were declines of 7.3% and 19.0% respectively. Recent price moves are set...

On March 13, 2026, Liquidia’s Chief Medical Officer Rajeev Saggar sold 35,365 shares of common stock for about US$1.28 million, trimming roughly one sixth of his direct holdings. This sizeable insider sale comes while Liquidia’s core business appears to be progressing, highlighted by YUTREPIA’s reach to more than 2,900 patients and two straight profitable quarters. We’ll now examine how this sizeable insider sale amid ongoing YUTREPIA momentum may influence Liquidia’s broader investment...

What recent price moves suggest about Sify Technologies (SIFY) Sify Technologies (SIFY) has seen sharp swings recently, with a 3.1% decline over the past day, a 7.1% drop across the past week, and a 20.4% slide over the past month. See our latest analysis for Sify Technologies. The recent slide in Sify Technologies' share price contrasts with its very large 1 year total shareholder return of 193.85%. At the same time, the 5 year total shareholder return of a 40.28% loss underlines how quickly...

Stryker (SYK) is back in focus after a cyberattack disrupted its manufacturing and electronic ordering systems, with the company now reporting restored access across most sites and renewed progress on production and fulfillment. See our latest analysis for Stryker. The recent cyberattack headlines come after a weaker patch for the stock, with a 30 day share price return of a 14.7% decline and a 1 year total shareholder return of a 9.3% loss, pointing to fading momentum despite positive multi...

Earlier this week, Progress Software announced that its ShareFile document collaboration platform now supports eIDAS-compliant Advanced and Qualified Electronic Signatures for UK and EU customers, integrating identity verification via Qualified Trust Service Providers into a single, auditable workflow. This move positions ShareFile as an all-in-one workspace for regulated industries, consolidating collaboration, high-assurance signing, and secure storage without relying on separate...

Earlier this week, Gates Industrial Corporation, a manufacturer of engineered power transmission and fluid power solutions, was lifted by easing geopolitical tensions as postponed military action against Iran reduced perceived risk for globally exposed industrial companies. This shift in geopolitical risk sentiment matters for Gates because its end markets, including construction equipment and manufacturing, are closely tied to global economic stability and confidence in longer-term capital...

If you are wondering whether Ligand Pharmaceuticals at around US$195 a share still offers value, the next sections will walk through what the current price might be implying about the business. The stock has delivered an 81.6% return over 1 year and 165.7% over 3 years, while the shorter term picture shows a 4.6% decline over 7 days alongside modest gains of 2.1% over 30 days and 2.8% year to date. Recent coverage of Ligand Pharmaceuticals has focused on its role in the wider pharmaceuticals...

Sportradar Group (NasdaqGS:SRAD) has introduced Playradar, a new iGaming brand that combines live sports streaming with casino style gaming experiences. The company has also expanded its relationship with Hard Rock Bet to include official PGA TOUR and UFC data plus more advanced in play betting features. These updates extend Sportradar's role beyond core sports data into hybrid gaming products while deepening ties with a major US betting operator. Sportradar Group, trading at $17.15, is...

On March 16, 2026, at its Global Conference, XP Inc. drew attention as analysts highlighted a stronger-than-expected start to the year driven by heavier retail equity trading and anticipated client reimbursements from Brazil’s deposit insurance fund (FGC) flowing back into XP’s platform. The interesting angle for investors is how these FGC-related inflows, if reinvested into fixed-income products, could generate upfront commissions that temporarily enhance XP’s revenue mix and fee...

In recent commentary on Cullen/Frost Bankers, analysts highlighted that while Frost Bank’s prior quarterly results were solid, its revenue growth over the past two years has slowed relative to peers and its own five-year trend. An interesting takeaway is that consensus now points to a projected decline in tangible book value per share over the next 12 months, raising fresh questions about the bank’s capital generation and profitability outlook. Next, we’ll examine how slowing revenue growth...

On 19 March 2026, X-energy Reactor Company and Talen Energy signed a Letter of Intent to assess deploying X-energy's Xe-100 small modular reactors in Pennsylvania and across the PJM market, including feasibility studies, site evaluations, and a potential transition of fossil-fired sites to nuclear. This early-stage collaboration highlights a possible path for Talen to expand clean baseload capacity while reusing existing transmission infrastructure and workforce at legacy fossil generation...

Cushman & Wakefield recently appointed Victoria Lake as CFO for APAC and EMEA and released its 2026 Americas Office Fit Out Cost Guide, which reports a 5.5% year-over-year rise in office fit-out costs across 59 markets. The guide’s findings, including contractors’ expectations of further labor and material cost increases amid a 25-year low office construction pipeline, highlight mounting cost pressures that could influence how landlords, tenants, and investors approach office space...

If you are wondering whether Boyd Gaming is priced fairly or if the market is missing something, this breakdown will help you assess what you are really paying for at the current share price. The stock last closed at US$80.16, with a 1.1% decline over the past week and a 5.6% decline over the past month. Over longer periods, the 1 year return is 22.1%, and the 3 year and 5 year returns are 28.8% and 36.1% respectively. Recent attention on Boyd Gaming has focused on its share price...

Aptiv (NYSE:APTV) announced that Javed Khan, Executive Vice President and President of Intelligent Systems, is resigning to become CEO of a software and AI company. CEO Kevin Clark will take on Khan's responsibilities on an interim basis while Aptiv searches for a successor. Aptiv shares recently closed at $67.04, with the stock showing a 10.6% gain over the past year, a 14.5% decline year to date, and a 40.2% decline over three years. The Intelligent Systems segment is an important area...

If you are wondering whether Corpay's current share price reflects its underlying worth, you are not alone. This article focuses squarely on what you might be paying for each dollar of quality in the business. Corpay recently closed at US$284.93, with returns of a 0.9% decline over 7 days, a 13.7% decline over 30 days, a 5.2% decline year to date, a 17.8% decline over 1 year, alongside longer term returns of 35.1% over 3 years and 1.9% over 5 years. Recent coverage has highlighted Corpay in...